Chemotherapeutics of visceral leishmaniasis: present and future developments
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chemotherapeutics of visceral leishmaniasis: present and future developments
Authors
Keywords
-
Journal
PARASITOLOGY
Volume 145, Issue 04, Pages 481-489
Publisher
Cambridge University Press (CUP)
Online
2017-12-07
DOI
10.1017/s0031182017002116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protective Efficacy of Secondary Prophylaxis Against Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients Over the Past 10 Years in Eastern India
- (2016) Rama P. Goswami et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Elimination of visceral leishmaniasis on the Indian subcontinent
- (2016) Om Prakash Singh et al. LANCET INFECTIOUS DISEASES
- Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India
- (2015) Raman Mahajan et al. CLINICAL INFECTIOUS DISEASES
- Combination Therapy with Amphotericin-B and Miltefosine for Post-kala-azar Dermal Leishmaniasis: A Preliminary Report
- (2014) V Ramesh et al. ACTA DERMATO-VENEREOLOGICA
- HIV and Visceral Leishmaniasis Coinfection in Bihar, India: An Underrecognized and Underdiagnosed Threat Against Elimination
- (2014) Sakib Burza et al. CLINICAL INFECTIOUS DISEASES
- Asymptomatic Leishmania Infection: A New Challenge for Leishmania Control
- (2014) O. P. Singh et al. CLINICAL INFECTIOUS DISEASES
- Investigational drugs for visceral leishmaniasis
- (2014) Shyam Sundar et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- An update on pharmacotherapy for leishmaniasis
- (2014) Shyam Sundar et al. EXPERT OPINION ON PHARMACOTHERAPY
- Post kala-azar dermal leishmaniasis: an unresolved mystery
- (2014) Debanjan Mukhopadhyay et al. TRENDS IN PARASITOLOGY
- Five-Year Retrospective Italian Multicenter Study of Visceral Leishmaniasis Treatment
- (2013) Francesco Di Masi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- One-Year Follow-up of Immunocompetent Male Patients Treated With Miltefosine For Primary Visceral Leishmaniasis in Bihar, India
- (2013) S. Burza et al. CLINICAL INFECTIOUS DISEASES
- Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance
- (2013) Suman Rijal et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study
- (2013) Dinesh Mondal et al. Lancet Global Health
- Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use
- (2012) S. Sundar et al. CLINICAL INFECTIOUS DISEASES
- Leishmaniasis: an update of current pharmacotherapy
- (2012) Shyam Sundar et al. EXPERT OPINION ON PHARMACOTHERAPY
- Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial
- (2012) Shyam Sundar et al. TROPICAL MEDICINE & INTERNATIONAL HEALTH
- Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh
- (2011) Mahmudur Rahman et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis
- (2011) V. Ramesh et al. BRITISH JOURNAL OF DERMATOLOGY
- Liposomal Amphotericin B for Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients: 2-Year Treatment Outcomes in Bihar, India
- (2011) P. K. Sinha et al. CLINICAL INFECTIOUS DISEASES
- Limited Effectiveness of High-Dose Liposomal Amphotericin B (AmBisome) for Treatment of Visceral Leishmaniasis in an Ethiopian Population With High HIV Prevalence
- (2011) K. Ritmeijer et al. CLINICAL INFECTIOUS DISEASES
- Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
- (2011) Shyam Sundar et al. LANCET
- A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis
- (2011) Jaya Chakravarty et al. VACCINE
- A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries
- (2011) Suerie Moon et al. Globalization and Health
- Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, India
- (2010) Prabhat K. Sinha et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Evaluation of Ex Vivo Human Immune Response against Candidate Antigens for a Visceral Leishmaniasis Vaccine
- (2010) Rajiv Kumar et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
- (2010) Shyam Sundar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ambisome plus miltefosine for Indian patients with kala-azar
- (2010) Shyam Sundar et al. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
- Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal - the challenges for diagnosis and treatment
- (2010) Shyam Sundar et al. TROPICAL MEDICINE & INTERNATIONAL HEALTH
- Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis—A meta-analysis
- (2009) Sassan Noazin et al. VACCINE
- New Treatment Approach in Indian Visceral Leishmaniasis: Single‐Dose Liposomal Amphotericin B Followed by Short‐Course Oral Miltefosine
- (2008) Shyam Sundar et al. CLINICAL INFECTIOUS DISEASES
- The Relationship between Leishmaniasis and AIDS: the Second 10 Years
- (2008) J. Alvar et al. CLINICAL MICROBIOLOGY REVIEWS
- Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis
- (2008) Eugenia Carrillo et al. VACCINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started